Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue.Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.
